CT radiomic analysis using lymph-node-density profile in correlation to SUV-value for PET/CT based N-Staging

In patients with lung cancer (LC), malignant melanoma (MM), gastroenteropancreatic neuroendocrine tumours (GEP-NETs) and prostate cancer (PCA), N-staging is often performed by integrated (18)F-FDG-Positron Emission Tomography/Computed Tomography (PET/CT) (LC, MM), (68)Ga-DOTATOC-PET/CT (GEP-NET) and (68)Ga-PSMA-PET/CT (PCA): N-staging is not always accurate due to indeterminate PET-findings. To better evaluate malignant lymph node (LN) infiltration, additional surrogate parameters, especially in cases with indeterminate PET-findings, would be helpful. The purpose of this study was to evaluate if maximal standardized uptake values (SUVmax) in the PET-examination might correlate with semi-automated density measurements of LN in the CT-component of the integrated PET/CT examination.

After approval by the institutional review board, 1022 LNs in PET/CT-examinations of 148 patients were retrospectively analysed (LC: 327 LN out of 40 patients, MM: 224 LN out of 33 patients; GEP-NET: 217 LN out of 35 patients, PCA: 254 LN out of 40 patients). PET/CT was performed before surgery/biopsy, chemotherapy, or internal or external radiation therapy, according to the clinical schedule, patients with prior chemotherapy or radiation therapy were ruled out. LN analyses were performed on the basis of SUV-uptake 60 minutes after tracer injection and volumetric CT histogram analysis in non-contrast enhanced CT.

LNs were considered positive or negative on the basis of tracer uptake, histological confirmation was not available. Of the 1022 lymph nodes, 331 had positive SUVmax-findings (3-times SUVmax of bloodpool), 86 were indeterminate (1-3 SUVmax bloodpool), 605 were negative (< SUVmax bloodpool). LNs with positive SUV-uptake had significantly higher CT-density values compared to PET-negative LN, irrespective of the cancer entity.

Density measurements of LNs in patients with LC, MM, GEP-NET and PCA correlate with FDG uptake in PET, and might therefore serve as an additional surrogate parameter for the differentiation between malignant and benign LNs. A possible density threshold in clinical routine might be a 7.5 Hounsfield Units (HU) cut-off value to differentiate between malignant and benign LN infiltration, and a 20 HU cut off to exlude benign lymph node processes, especially helpful in PET-indeterminate LNs.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2016 Sep 22 [Epub ahead of print]

Frederik Giesel, Florian Schneider, Clemens Kratochwil, Daniel Rath, Tim Holland-Letz, Jan Moltz, Hans-Ulrich Kauczor, Lawrence Schwartz, Uwe Haberkorn, Paul Flechsig

University Hospital Heidelberg, Germany;, Core Facility of Statistics, German Cancer Research Center, Heidelberg;, Fraunhofer MEVIS, Institute for Medical Image Computing, Bremen;, Columbia, United States.


Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.